Download PDF
Thromb Haemost 2001; 85(02): 349-355
DOI: 10.1055/s-0037-1615691
Review Article
Schattauer GmbH

Purification of Proplatelet Formation (PPF) Stimulating Factor: Thrombin/Antithrombin III Complex Stimulates PPF of Megakaryocytes In Vitro and Platelet Production In Vivo

Yoji Ishida
1   Division of Hematology, IIIrd Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan
,
Kazuo Yano
2   Bio-Science Laboratory, Life Science Research Laboratories, Asahi Chemical Industry, Fuji, Shizuoka, Japan
,
Toshiharu Ito
1   Division of Hematology, IIIrd Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan
,
Hiroki Shigematus
2   Bio-Science Laboratory, Life Science Research Laboratories, Asahi Chemical Industry, Fuji, Shizuoka, Japan
,
Kohsuke Sasaki
3   Department of Pathology, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan
,
Shuhei Kondo
2   Bio-Science Laboratory, Life Science Research Laboratories, Asahi Chemical Industry, Fuji, Shizuoka, Japan
,
Shin-Ichiro Kuriya
1   Division of Hematology, IIIrd Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan
› Author Affiliations
Further Information

Publication History

Received 12 April 2000

Accepted after resubmission 18 September 2000

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

In this study, the protein which stimulates proplatelet formation (PPF) of megakaryocytes was purified from normal human plasma using 7 steps procedures. Two different protease inhibitors were identified based on their amino acid sequences, i.e. antithrombin III (AT III) and C1 inhibitor. They were included in high density lipoprotein (HDL). HDL was necessary for AT III to be active in PPF in vitro. The biological effects of the AT III /HDL or thrombin-AT III (TAT)/HDL were studied in vitro. PPF of murine megakaryocytes was stimulated by negative control (BSA) (1.8 ± 0.3%), AT III (2.0 ± 0.4%), HDL (1.2 ± 0.9%), AT III /HDL (14.8 ± 2.1%) or TAT/HDL (23.3 ± 3.5%), respectively. TAT/HDL also had a synergistic effect with the mpl ligand, judging by the acetylcholinesterase (AchE) expression of murine megakaryocytes (2.7 fold increase). In vivo subcutaneous administration of AT III alone or TAT for 3 days significantly stimulated thrombocytosis (136% and 144%, respectively, p <0.05) and AT III/HDL showed rapid and further stimulation (150%, p <0.01). These results and the previous studies indicate that megakaryocytopoiesis is regulated by the mpl ligand, while a protease/protease inhibitor complex such as TAT, which is involved in the coagulation cascade associated with platelet consumption, might be one of the regulators in platelet production.

Keywords

Thrombocytopoiesis - proplatelet formation stimulating factor - anti-thrombin III - thrombin - high density lipoprotein
 

  • References

  • 1 de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, Oles KJ, Hultgren B, Solberg Jr LA, Goeddel DV, Eaton DL. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand [see comments]. Nature 1994; 369 6481 533-8.
    CrossrefPubMedGoogle Scholar
  • 2 Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, Roth T, Papayannopoulou DC. Foster. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin [see comments]. Nature 1994; 369 6481 568-71.
    CrossrefPubMedGoogle Scholar
  • 3 Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Pres-nell SR, O’Hara PJ, Hagen FS, Roth GJ, Foster DC. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo [see comments]. Nature 1994; 369 6481 565-8.
    CrossrefPubMedGoogle Scholar
  • 4 Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W. cMpl ligand is a humoral regulator of megakaryocytopoiesis [see comments]. Nature 1994; 369 6481 571-4.
    CrossrefPubMedGoogle Scholar
  • 5 Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proceedings of the National Academy of Sciences of the United States of America 1995; 92 (Suppl. 08) 3234-8.
    CrossrefPubMedGoogle Scholar
  • 6 Debili N, Wendling F, Katz A, Guichard J, Breton-Gorius J, Hunt P, Vainchenker W. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995; 86 (Suppl. 07) 2516-25.
    PubMedGoogle Scholar
  • 7 Bunting S, Widmer R, Lipari T, Rangell L, Steinmetz H, Carver-Moore K, Moore MW, Keller GA, de Sauvage FJ. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood 1997; 90 (Suppl. 09) 3423-9.
    PubMedGoogle Scholar
  • 8 Radley JM, Scurfield G. The mechanism of platelet release. Blood 1980; 56: 996-9.
    PubMedGoogle Scholar
  • 9 Leven RM, Yee MK. Megakaryocyte morphogenesis stimulated in vitro by whole and partially fractionated thrombocytopenic plasma: model system for the study of platelet formation. Blood 1987; 69 (Suppl. 04) 1046-52.
    PubMedGoogle Scholar
  • 10 Stenberg EP, Levin J. Mechanisms of platelet production. Blood Cells 1989; 15: 23-47.
    PubMedGoogle Scholar
  • 11 Topp SK, Tablin F, Levin J. Culture of isolated bovine megakaryocytes on reconstituted basement membrane matrix leads to proplatelet process formation. Blood 1990; 76: 912-29.
    PubMedGoogle Scholar
  • 12 Choi SE, Nichol JL, Hokom M, Horkohl CA. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Blood 1995; 85: 402-13.
    PubMedGoogle Scholar
  • 13 Leven RM, Clark B, Tablin F. Effect of recombinant interleukin-6 and thrombopoietin on isolated guinea pig bone marrow megakaryocyte protein phosphorylation and proplatelet formation. Blood Cells, Molecules and Diseases 1997; 23 (Suppl. 02) 252-68.
    CrossrefPubMedGoogle Scholar
  • 14 Nagahisa H, Nagata Y, Ohnuki T, Osada M, Nagasawa T, Abe T, Todokoro K. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood 1996; 87 (Suppl. 04) 1309-16.
    PubMedGoogle Scholar
  • 15 Ito T, Ishida Y, Kashiwagi R, Kuriya S. Recombinant human c-Mpl ligand is not a direct stimulator of proplatelet formation in mature human megakaryocytes. British Journal of Haematology 1996; 94 (Suppl. 02) 387-90.
    CrossrefPubMedGoogle Scholar
  • 16 Choi ES, Hokom MM, Chen JL, Skrine J, Faust J, Nichol J, Hunt P. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. British Journal of Haematology 1996; 95 (Suppl. 02) 227-33.
    PubMedGoogle Scholar
  • 17 Ishida Y, Ito T, Kuriya S. Effects of C-Mpl ligand on cytoplasmic maturation of murine megakaryocytes and on platelet production. J Histochem Cytochem 1998; 46 (Suppl. 01) 49-57.
    CrossrefPubMedGoogle Scholar
  • 18 Karnovsky M, Root LA. ‘direct-coloring’ thiocholine method for cholinesterases. J Histochem Cytochem 1964; 12: 219-221.
    CrossrefPubMedGoogle Scholar
  • 19 Edelstein C, Lim CT, Scanu AM. On the subunit structure of the protein of human serum high density lipoprotein. I. A study of its major polypeptide component (Sephadex, fraction 3).. Journal of Biological Chemistry. 1972; 247 (Suppl. 18) 5842-9.
    PubMedGoogle Scholar
  • 20 Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
    CrossrefPubMedGoogle Scholar
  • 21 Burstein SA, Boyd CN, Dale GL. Quantitation of megakaryocytopoiesis in liquid culture by enzymatic determination of acetylcholinesterase. J Cell Physiol 1985; 122 (Suppl. 01) 159-65.
    CrossrefPubMedGoogle Scholar
  • 22 Kato H, Nakanishi T, Arai H, Nishida I, Nishida T. Purification, microheterogeneity and stability of human lipid transfer protein.. J Biol Chem 1989; 264: 4082-7.
    PubMedGoogle Scholar
  • 23 Hunt P, Hokom MM, Wiemann B, Leven RM, Arakawa T. Megakaryocyte proplatelet-like process formation in vitro is inhibited by serum prothrombin, a process which is blocked by matrix-bound glycosaminoglycans. Experimental Hematology 1993; 21 (Suppl. 02) 372-81.
    PubMedGoogle Scholar
  • 24 Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87 (Suppl. 10) 4068-71.
    PubMedGoogle Scholar
  • 25 Odell TT, Murphy JR, Jackson CW. Stimulation of megakaryocytopoiesis by acute thrombocytopenia in rats. Blood 1976; 48 (Suppl. 05) 765-75.
    PubMedGoogle Scholar
  • 26 Corash L, Chen HY, Levin J, Baker G, Lu H, Mok Y. Regulation of thrombopoiesis: effects of the degree of thrombocytopenia on megakaryocyte ploidy and platelet volume. Blood 1987; 70 (Suppl. 01) 177-85.
    PubMedGoogle Scholar
  • 27 Ebbe S, Yee T, Carpenter D, Phalen E. Megakaryocytes increase in size within ploidy groups in response to the stimulus of thrombocytopenia. Experimental Hematology 1988; 16 (Suppl. 01) 55-61.
    PubMedGoogle Scholar
  • 28 Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86 (Suppl. 01) 54-9.
    PubMedGoogle Scholar
  • 29 Miyazaki H. Cloning of thrombopoietin and its therapeutic potential. Cancer Chemotherapy & Pharmacology 1996; 38 Suppl S74-7.
    CrossrefPubMedGoogle Scholar
  • 30 Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74 (Suppl. 04) 1241-4.
    PubMedGoogle Scholar
  • 31 Carrington PA, Hill R, Stenberg PE, Levin J, Corash L, Schreurs J, Baker G, Levin FC. Multiple in vivo effects of interleukin-3 and inter-leukin-6 on murine megakaryocytopoiesis. Blood 1991; 77 (Suppl. 01) 34-41.
    PubMedGoogle Scholar
  • 32 Rinder HM, Schuster JE, Rinder CS, Wang C, Schweidler HJ, Smith BR. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998; 91 (Suppl. 04) 1288-94.
    CrossrefPubMedGoogle Scholar
  • 33 Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85 (Suppl. 10) 2720-30.
    PubMedGoogle Scholar
  • 34 Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thrombosis & Haemostasis 1997; 77 (Suppl. 05) 808-14.
    PubMedGoogle Scholar
  • 35 Kuefer MU, Wang WC, Head DR, Wilimas JA, Furman WL, Liu Q, Hornkohl AC, Best DM, Jackson CW. Thrombopoietin level in young patients is related to megakaryocyte frequency and platelet count. Journal of Pediatric Hematology/Oncology 1998; 20 (Suppl. 01) 36-43.
    CrossrefPubMedGoogle Scholar